Sandoz acquires cancer-treatment maker
HOLZKIRCHEN, Germany The generics arm of Swiss pharmaceutical company Novartis has completed its acquisition of an Austrian company that makes injectable drugs to treat cancer.
Sandoz announced that it had acquired EBEWE Pharma for $1.3 billion, adding 15 new generic drugs to its portfolio of marketed drugs and more to the pipeline.
“We are delighted to combine EBEWE Pharma’s portfolio and pipeline of high-quality injectables with our global leadership in biopharmaceuticals, anti-infectives and other innovative technologies,” Sandoz CEO Jeff George said in a statement. “This will greatly enhance the range of affordable generic anti-cancer medicines Sandoz offers to patients worldwide.”
Teva to market antipsychotic generic
JERUSALEM A generic drug maker announced that a court of appeals upheld a decision regarding a patent of a popular antipsychotic medication.
Teva said that the U.S. Court of Appeals for the Federal Circuit affirmed a July 1, 2008 decision by the District Court to grant AstraZeneca’s motion for summary judgment of no inequitable conduct related to U.S. Patent No. 4,879,288.
As a result of the decision, Teva expects to market its generic version of AstraZeneca’s antipsychotic Seroquel (quetiapine fumarate tablets) no later than March 2012, when the patent is otherwise set to expire.
American Diabetes Association, Ad Council launch new ads, online tools
NEW YORK The American Diabetes Association and the Ad Council, working with the National Council of La Raza and the American Association of Diabetes Educators, are joining to launch a new series of national public service advertisements and online tools designed to raise awareness of the risks of uncontrolled diabetes and help those Americans with diabetes take the first steps toward staying healthy.
The PSAs illustrate how serious complications of diabetes can arise suddenly and without warning, and encourage those with diabetes to proactively engage their healthcare providers in a conversation about understanding and managing their risk factors. The ads are an extension of the American Diabetes Association and Ad Council’s national multimedia campaign, which first launched in 2007.
“These PSAs are what we need to further educate people with diabetes about the deadly complications that can occur if one does not properly manage his or her disease,” said R. Paul Robertson, M.D., president medicine and science for the American Diabetes Association. “We are excited to once again continue our collaboration with the Ad Council to reach hundreds of communities in need of education. Education is a key component to changing the future of diabetes.”
The campaign drives audiences to visit two new Web sites: www.diabetesactnow.org and Spanish language site www.diabetesactuaya.org. The Web sites give adults with Type 1 or Type 2 diabetes friendly, supportive places to get simple answers and learn easy actions to help reduce and/or prevent complications. Each site features a diabetes healthcare professional who explains why people with diabetes need to know their ABCs (A1C – a measure of average glucose, blood pressure, cholesterol), and includes a library of entertaining videos designed to help users make easy lifestyle changes to improve their diabetes numbers.